ENDRA Life Sciences Inc. (NASDAQ: NDRA)

ENDRA Life Sciences Inc. develops a next-generation enhanced ultrasound technology platform called Thermo-Acoustic Enhanced Ultrasound (TAEUS). The company focuses on using TAEUS to measure liver fat as a biomarker for metabolic diseases and to support the management of GLP-1 receptor agonist therapies. Its goal is to provide an accurate, simple-to-use, inexpensive point-of-care test that functions like a blood pressure cuff for metabolic health assessment. Beyond liver fat measurement, the TAEUS platform is being developed for temperature monitoring during thermoablative procedures, vascular imaging, and tissue perfusion assessment. The company also envisions using TAEUS to support therapeutic monitoring in cardiology and oncology applications.

The company intends to generate revenue primarily through a low barrier-to-entry multi-year subscription-based model that delivers monthly recurring revenue. It will retain a traditional direct product sale option accompanied by annual upgrade and maintenance fees for customers who prefer that approach. In either model, sales are executed by a direct sales force that leverages clinical data from established reference sites to demonstrate value. Additionally, ENDRA plans to license its TAEUS technology to original equipment manufacturers for integration into their ultrasound and thermoablative systems. Revenue from licensing agreements is expected to include upfront fees and ongoing royalties based on sales of incorporated systems.

ENDRA operates in the competitive medical diagnostics ultrasound market where it faces established players such as GE Healthcare, Royal Philips, Siemens Healthineers, Canon Corporation, and Fujifilm Corporation. These competitors offer conventional ultrasound, MRI, and CT systems that dominate imaging markets but lack the specific tissue composition and temperature measurement capabilities of TAEUS. The company's competitive advantage lies in its proprietary thermoacoustic technology which enables ultrasound systems to differentiate fat from lean tissue, monitor tissue temperature in real time, visualize blood vessels with a saline contrast agent, and assess tissue perfusion without ionizing radiation. By providing these functions as an add-on to existing ultrasound scanners, ENDRA aims to deliver a cost-effective, point-of-care alternative to expensive MRI scans and invasive biopsies for liver fat assessment and related applications. This combination of lower cost, point-of-care usability, and absence of radiation exposure positions ENDRA to capture share in markets where traditional imaging is impractical or prohibitively expensive.

The company’s customer base consists of pharmaceutical companies and contract research organizations that require liver fat biomarkers for GLP-1 drug trials, high-end primary care networks seeking advanced metabolic health screening, bariatric and metabolic clinics managing obesity and related disorders, and broad primary and internal medicine providers focused on disease prevention and therapy monitoring. While the filing does not disclose specific customer names, these groups represent the primary ENDRA targets for its TAEUS liver device and future platform applications. ENDRA also anticipates serving specialized users such as interventional radiologists and surgical oncologists who require real-time temperature guidance during ablation therapies.